• CLS registered a directed issue of units with Sweden’s Companies Registration Office, increasing shares outstanding to 48,516,242.
• Outstanding TO 9 B warrants total 13,012,236; each warrant subscribes for one new B-share at SEK 1.9.
• TO 9 B exercise window runs March 1–15, 2027; last trading day expected March 11, 2027.
• Full exercise could raise about SEK 24.7 million gross; transaction costs estimated at about SEK 1.6 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CLS - Clinical Laserthermia Systems AB published the original content used to generate this news brief via Cision (Ref. ID: 20260907:BIT:7216:0) on September 07, 2026, and is solely responsible for the information contained therein.